



CORRECTION

Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma

Thomas R. Jeffry Evans¹, Masatoshi Kudo², Richard S. Finn³, Kwang-Hyub Han⁴, Ann-Lii Cheng⁵, Masafumi Ikeda⁶, Silvija Kraljevic⁷, Min Ren⁸, Corina E. Dutcus⁸, Fabio Piscaglia⁹ and Max W. Sung¹⁰

British Journal of Cancer (2019) 121:625; <https://doi.org/10.1038/s41416-019-0534-2>

Correction to: *British Journal of Cancer*; <https://doi.org/10.1038/s41416-019-0506-6>; published online 28 June 2019.

This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

¹University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK; ²Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan; ³David Geffen School of Medicine, UCLA Medical Center, Los Angeles, CA, USA; ⁴Severance Hospital, Yonsei University, Seoul, South Korea; ⁵National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan; ⁶Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; ⁷Former employee of Eisai Ltd, Hatfield, UK; ⁸Eisai Inc., Woodcliff Lake, NJ, USA; ⁹Unit of Internal Medicine, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy and ¹⁰Tisch Cancer Institute at Mount Sinai, New York, NY, USA
Correspondence: Thomas R. Jeffry Evans (j.evans@beatson.gla.ac.uk)

Published online: 30 July 2019